Compound: Alogliptin
SMILES: O=c1n(c(N2C[C@H](N)CCC2)cc(n1C)=O)Cc3c(C#N)cccc3
InChIKey: ZSBOMTDTBDDKMP-OAHLLOKOSA-N
Synonyms: Alogliptin, 850649-61-5, alogliptina, alogliptine, vipidia, alogliptinum, JHC049LO86, 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile, HSDB 8203, CHEBI:72323, DTXSID90234130, 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile, alogliptin tartrate, 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile, RefChem:57142, A10BH04, DTXCID90156621, Benzonitrile, 2-((6-((3R)-3-amino-1-piperidinyl)-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl)methyl)-, (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile, Alogliptin [INN], MFCD09833196, 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile, 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile, (R)-2-[6-[3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]benzonitrile, Benzonitrile,2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-, UNII-JHC049LO86, 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile, 1246610-75-2, 1347001-80-2, 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile; (R)-2-[6-[3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]benzonitrile; 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile; Alogliptin, Alogliptin (Standard), ALOGLIPTIN [MI], Trelagliptin Impurity 30, ALOGLIPTIN [VANDF], ALOGLIPTIN [WHO-DD], SCHEMBL121028, CHEMBL376359, GTPL6319, HY-A0023AR, orb1300993, orb3141143, SCHEMBL29352995, BDBM16285, HY-A0023A, ZSBOMTDTBDDKMP-OAHLLOKOSA-N, ALBB-038593, EX-A5446, Alogliptin pound SYR-322 pound(c), EBC-26650, MSK177669, s2868, s5365, AKOS025149226, CCG-267914, CCG-267915, CS-1617, DB06203, FA17319, 2-[[6-[(3R)-3-amino-1-piperidyl]-3-methyl-2,4-dioxo-pyrimidin-1-yl]methyl]benzonitrile, NCGC00386215-04, NCGC00386215-05, AC-26300, AS-19582, SY077741, NS00071194, SW219186-1, EN300-6482025, F468425, Q4734170, BRD-K83003151-001-02-2, BRD-K83003151-001-03-0, BRD-K83003151-057-02-4, 2-{6-[3(R)-Amino-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile
Theoretical properties:
molecular_formula: C18H21N5O2
molecular_weight: 339.4 g/mol
exact_mass: 339.16952493 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 3
heavy_atom_count: 25
topological_polar_surface_area: 93.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: Sparingly soluble
Descriptions:
pubchem: Alogliptin is a piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes. It has a role as a hypoglycemic agent and an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor. It is a nitrile, a member of piperidines, a member of pyrimidines and a primary amino compound. It is a conjugate base of an alogliptin(1+).
chebi: A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the <i>R</i>-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes.
chembl: ALOGLIPTIN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Alogliptin, sold under the brand names Nesina and Vipidia, is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.
In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about increased risk of heart failure. It was developed by Syrrx, a company which was acquired by Takeda Pharmaceutical Company in 2005. In 2020, it was the 295th most commonly prescribed medication in the United States, with more than 1 million prescriptions.